Weissel M, Zielinski C C, Hauff W, Till P
Medizinischen Universitätskliniken III, Wien.
Acta Med Austriaca. 1993;20(1-2):9-13.
This study reports our experience with a combined treatment with cyclosporin A (Cy A) and cortisone in patients with Graves' ophthalmopathy (GO), all of whom had compressive optic nerve disease (CON). The therapy was performed in 8 patients (6 females, age range: 40 to 76 years) with normal liver and kidney function and classical Graves' disease, except for 1 male, who had normal thyroid function and no detectable thyroid antibodies. 5 patients were euthyroid on methimazole, 2 patients were off thyrostatic treatment for 5 and 2 years. 3 patients have had high-dose cortisone (100 mg/die) treatment for GO before the study. Visual field defects were reported by the patients 1 week before start of therapy and evaluated by computerized visual field measurements (CVFM). The treatment consisted of Cy A in a dose which aimed at through levels between 100 and 300 ng/ml (RIA method) for 2 to 6 months and of methylprednisolone in a starting dose of 1 mg/kg body weight, tapered gradually to a maintenance dose of 10 mg/day for 6 to 12 months. CON disappeared completely in all patients. The thickening of affected eye muscles decreased in 5 patients, disappeared in 1 and remained unchanged in 2 patients. The shortest period for a measurable effect (either by echography or by CVFM, performed every week the first month and then every 3 months) was 1 week; the longest 1 month. The follow-up of the patients (range 6 months to 2.5 years) showed a relapse only in 1 patient. 2 patients were lost to follow-up 1 year after treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究报告了我们对格雷夫斯眼病(GO)患者联合使用环孢素A(Cy A)和可的松进行治疗的经验,所有这些患者均患有压迫性视神经疾病(CON)。该治疗方法应用于8例患者(6例女性,年龄范围:40至76岁),他们肝功能和肾功能正常,患有典型的格雷夫斯病,但有1例男性患者甲状腺功能正常且未检测到甲状腺抗体。5例患者服用甲巯咪唑后甲状腺功能正常,2例患者分别停用抗甲状腺药物5年和2年。3例患者在研究前曾接受高剂量可的松(100mg/日)治疗GO。患者在治疗开始前1周报告视野缺损,并通过计算机视野测量(CVFM)进行评估。治疗方案包括:Cy A剂量旨在使血药浓度维持在100至300ng/ml之间(放射免疫分析法),持续2至6个月;甲泼尼龙起始剂量为1mg/kg体重,逐渐减量至维持剂量10mg/日,持续6至12个月。所有患者的CON均完全消失。5例患者患眼眼肌增厚减轻,1例消失,2例不变。可测量到效果(通过超声检查或CVFM,第一个月每周进行一次,之后每3个月进行一次)的最短时间为1周,最长为1个月。患者随访(范围为6个月至2.5年)显示仅1例患者复发。2例患者在治疗1年后失访。(摘要截断于250字)